Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
CBCC Global Research Site:005, Manchester, Connecticut CBCC Global Research Site:006, Deerfield Beach, Florida CBCC Global Research Site:001, Augusta, Georgia CBCC Global Research Site:004, Carmel, Indiana CBCC Global Research Site:003, Fargo, North Dakota CBCC Global Research Site:002, Erie, Pennsylvania CBCC Global Research Site:007, Philadelphia, Pennsylvania Age range
50 Years and older
Last updated February 2025